Wild-type and mutated IDH1/2 enzymes and therapy responses

被引：175

作者：

Molenaar, Remco J. ^{[1
,2
,3
]}

Maciejewski, Jaroslaw P. ^{[3
]}

Wilmink, Johanna W. ^{[2
]}

van Noorden, Cornelis J. F. ^{[1
]}

机构：

[1] Acad Med Ctr, Canc Ctr Amsterdam, Dept Med Biol, Amsterdam, Netherlands

[2] Acad Med Ctr, Canc Ctr Amsterdam, Dept Med Oncol, Amsterdam, Netherlands

[3] Cleveland Clin, Dept Translat Hematol & Oncol Res, Cleveland, OH 44106 USA

来源：

ONCOGENE | 2018年 / 37卷 / 15期

基金：

美国国家卫生研究院;

关键词：

ACUTE MYELOID-LEUKEMIA; ISOCITRATE DEHYDROGENASE 1; PREDICT LONGER SURVIVAL; DNA-REPAIR ENZYMES; LOW-GRADE GLIOMAS; MUTANT IDH1; INTRAHEPATIC CHOLANGIOCARCINOMA; OXIDATIVE STRESS; TUMOR-CELLS; IN-VIVO;

D O I：

10.1038/s41388-017-0077-z

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Isocitrate dehydrogenase 1 and 2 (IDH1/2) are key enzymes in cellular metabolism, epigenetic regulation, redox states, and DNA repair. IDH1/2 mutations are causal in the development and/or progression of various types of cancer due to supraphysiological production of D-2-hydroxyglutarate. In various tumor types, IDH1/2-mutated cancers predict for improved responses to treatment with irradiation or chemotherapy. The present review discusses the molecular basis of the sensitivity of IDH1/2-mutated cancers with respect to the function of mutated IDH1/2 in cellular processes and their interactions with novel IDH1/2-mutant inhibitors. Finally, lessons learned from IDH1/2 mutations for future clinical applications in IDH1/2 wild-type cancers are discussed.

引用

页码：1949 / 1960

页数：12

共 50 条

[1] Wild-type and mutated IDH1/2 enzymes and therapy responses
Remco J. Molenaar
Jaroslaw P. Maciejewski
Johanna W. Wilmink
Cornelis J. F. van Noorden
Oncogene, 2018, 37 : 1949 - 1960
[2] Correction: Wild-type and mutated IDH1/2 enzymes and therapy responses
Remco J. Molenaar
Jaroslaw P. Maciejewski
Johanna W. Wilmink
Cornelis J. F. van Noorden
Oncogene, 2018, 37 : 5810 - 5810
[3] Wild-type and mutated IDH1/2 enzymes and therapy responses (vol 37, pg 1949, 2018)
Molenaar, Remco J.
Maciejewski, Jaroslaw P.
Wilmink, Johanna W.
van Noorden, Cornelis J. F.
ONCOGENE, 2018, 37 (43) : 5810 - 5810
[4] Energy Metabolism in IDH1 Wild-Type and IDH1-Mutated Glioblastoma Stem Cells: A Novel Target for Therapy?
van Noorden, Cornelis J. F.
Hira, Vashendriya V. V.
van Dijck, Amber J.
Novak, Metka
Breznik, Barbara
Molenaar, Remco J.
CELLS, 2021, 10 (03) : 1 - 16
[5] Wild-type IDH1: A molecular target in IDH1 mutant cancers
Wickenden, Julie A.
Russell, Paul
Smith, Amy
Henley, Tom
Elliott, Jane
Gitterman, Dan
Stockdale, Mark
Schofield, Christine
Torrance, Chris
Moore, Jonathan D.
CANCER RESEARCH, 2014, 74 (19)
[6] Disruption of Wild-Type IDH1 Suppresses D-2-Hydroxyglutarate Production in IDH1-Mutated Gliomas
Jin, Genglin
Reitman, Zachary J.
Duncan, Christopher G.
Spasojevic, Ivan
Gooden, David M.
Rasheed, B. Ahmed
Yang, Rui
Lopez, Giselle Y.
He, Yiping
McLendon, Roger E.
Bigner, Darell D.
Yan, Hai
CANCER RESEARCH, 2013, 73 (02) : 496 - 501
[7] WILD-TYPE IDH1 INHIBITS FERROPTOSIS IN GLIOBLASTOMA
Dunterman, Madeline
Korimerla, Navyateja
Murnan, Kevin
Tommasini-Ghelfi, Serena
Wahl, Daniel
Stegh, Alexander
NEURO-ONCOLOGY, 2024, 26
[8] Wild-Type IDH1 and Mutant IDH1 Opposingly Regulate Podoplanin Expression in Glioma
Sun, Chao
Xiao, Liming
Zhao, Yuanlin
Shi, Jiankuan
Yuan, Yuan
Gu, Yu
Zhang, Feng
Gao, Xing
Yang, Ying
Yang, Risheng
Qin, Junhui
Zhang, Jin
Wang, Chao
Wang, Yingmei
Wang, Zhe
Hu, Peizhen
Chang, Ting
Wang, Liang
Wang, Gang
Chen, Huangtao
Li, Zhuyi
Ye, Jing
TRANSLATIONAL ONCOLOGY, 2020, 13 (04):
[9] THE KETOGENIC DIET IS INEFFECTIVE IN PRECLINICAL MODELS OF IDH1 WILD-TYPE AND IDH1 MUTANT GLIOMA
Javier, Rodrigo
Horbinski, Craig
NEURO-ONCOLOGY, 2021, 23 : 208 - 208
[10] The Ketogenic Diet is Ineffective in Preclinical Models of IDH1 Wild-type and IDH1 Mutant Glioma
Horbinski, Craig
Javier, Rodrigo
JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY, 2021, 80 (06): : 563 - 563

← 1 2 3 4 5 →